Repare Therapeutics Inc RPTX

$2.65 +0.02 (0.76%)

Valuation

Market cap
114,236,000
Revenue TTM
$53,480,000
Net income TTM
$-84,690,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-158.36%
Debt to equity
0.00

Trading

Volume
1,219,900
Avg volume
1,340,526
Day's range
$2.62 – $2.65
Shares out
43,108,000
Stochastic %K
100%
Beta
0.97
Analysts
Moderate Buy
Price target
$3.00

Price

Company profile

Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics in Switzerland and the United States. The company uses its proprietary, genome-wide and CRISPR-enabled SNIPRx platform to discover and develop cancer therapies that treat cancers due to mechanisms of genomic instability, including DNA damage repair. It also develops camonsertib (RP-3500), a...

Show more

Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics in Switzerland and the United States. The company uses its proprietary, genome-wide and CRISPR-enabled SNIPRx platform to discover and develop cancer therapies that treat cancers due to mechanisms of genomic instability, including DNA damage repair. It also develops camonsertib (RP-3500), a potent and selective oral small molecule inhibitor of Ataxia-Telangiectasia and Rad3-related protein kinase that is in Phase 1/2 clinical trial for the treatment of solid tumors; and lunresertib (RP-6306), a selective and potent oral small molecule inhibitor of Protein Kinase Membrane-associated tyrosine-and threonine-specific cdc-2 inhibitory kinase that is in Phase 1/2 clinical trial. In addition, the company is developing RP-1664, an oral PLK4 inhibitor in Phase 1 clinical trial to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, an inhibitor of adenosinetriphosphatase activity on the helicase domain of DNA polymerase theta that is in Phase 1 clinical trial. The company has strategic collaborations with Hoffmann-La Roche Inc., F. HoffmannLa Roche Ltd, Debiopharm International S.A., Bristol-Myers Squibb Company, Ono Pharmaceutical Company Ltd., and New York University. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montreal, Canada. As of January 28, 2026, Repare Therapeutics Inc. operates as a subsidiary of Xenotherapeutics Inc.

Industry
Biotechnology
Sector
Healthcare
Phone
857 412 7018
Website
https://www.reparerx.com
Address
7171 Frederick-Banting, Building 2, Suite 270 St-Laurent, Montreal, Canada

Latest news

Stocktwits

89gt Jun 24, 7:40 PM
$ADTX let’s see it rip back to .059 like this morning. Nothing different or unexpected except the overreaction hand it to the shorts. Come on! $GDC $SKYQ $RPTX
1 replies
kuda8 May 22, 7:41 AM
$RPTX got today 0,197 euro per cvr .
0 replies
Investor6 Mar 31, 12:38 PM
$BARK And the previous of TLYS investment of Shay Capital was also successful, they made more than 50% in Repare Therapeutics, $RPTX
1 replies
Investor6 Feb 2, 9:55 AM
$RPTX On January 20, 2026, Shay Capital LLC, a prominent investment firm, executed a noteworthy transaction by acquiring 2,870,141 shares of Repare Therapeutics Inc. Shay Capital also supports the buyout offer for BARK from Marcus Lemonis with a premium of 22% by the current BARK share price. It was the second buyout offer for BARK, the first came from the insiders.
2 replies
atkud Jan 27, 9:04 PM
$RPTX i never sold my 1k shares. Can anyone explain to me the ramificatuons of the sale?
1 replies
hitmongreen Jan 26, 6:45 PM
$RPTX 🤔
0 replies
Mnof Jan 23, 5:15 PM
$RPTX Over 10 years if everything comes to fruition, then 1 CVR could be valued around $46 based on assuming at least $ 2bn sale of assets, or commercial catalysts and royalty streams assuming 43.1m shares outstanding and net proceeds according to % laid down by the Xeno agreement within this time frame https://ir.reparerx.com/news-releases/news-release-details/repare-therapeutics-enters-definitive-agreement-be-acquired and financially underwritten by Xoma https://xoma.com/ :) With around 43.1m shares outstanding and takeover supported by shares from BVF partners LP, Blue Owl and OrbiMed the current finalized deal of $30M for the pol theta deal with Gilead when 100% dispersed should have added around 70 cents to the share sale price of $1.80 quoted in Nov 2025 https://ir.reparerx.com/news-releases/news-release-details/repare-therapeutics-enters-definitive-agreement-be-acquired Meaning shareholders should minimally receive $2.52 plus 1 CVR for each share as currently reflected in the share price since the Gilead deal and not the $2.20 quoted in their recent release.
1 replies
TwongStocks Jan 21, 9:11 PM
$RPTX Equity Corporate Actions Alert #2026 - 36 Information Regarding the Merger of Repare Therapeutics Inc. (RPTX) https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2026-36 At a special meeting held on January 16, 2026, the shareholders of Repare Therapeutics Inc. (RPTX) approved the proposed merger with XenoTherapeutics, Inc. The merger is tentatively scheduled to close prior to the market open on January 28, 2026. In anticipation of the closing, the stock will be halted immediately following the after-hours session at or around 7:50 p.m. on January 27, 2026. If the merger closes as anticipated, the stock will remain halted on the day of closing (January 28th) and will be suspended effective January 29, 2026. RPTX shareholders will receive $2.20 and one CVR for each share held at closing.
0 replies